Melyssa specialises in radiopharmaceutical development, and radiobiological evaluation focused on targeted alpha therapy
Dr Melyssa Grieve is an ECR Postdoctoral Research Fellow at the Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, with expertise in radiochemistry, radiopharmaceutical development, and radiobiological evaluation focused on targeted alpha therapy. She completed her PhD at Monash University, undertaking research placements at the Centre for Advanced Imaging (UQ) and the Helmholtz‑Zentrum Dresden Rossendorf (Germany), where she gained extensive hands‑on experience with more than 15 radionuclides. Her research centres on the design, synthesis, and optimisation of radiopharmaceuticals for targeted radiotherapy, with particular strength in radiolabelling strategies for emerging therapeutic platforms. As a postdoctoral researcher, she contributes to industry‑partnered projects including a UQ–AdvanCell Linkage Project, and is an AMTAR Research Fellow and recipient of the 2025 ACRF Empowering Women in Cancer Research Preceptorship.
Key Publications
M. L. Grieve, P. R. W. J. Davey, P. V. Bernhardt, C. M. Forsyth and B. M. Paterson. “Rapid and stable complexation of the α-generators bismuth-212 and lead-212 with a tetraazamacrocyclic chelator bearing thiosemicarbazone pendant arms” , Inorganic Chemistry Frontiers 2024, 11(21): 7307 - 7323. https://doi.org/10.1039/D4QI01338G
M. L. Grieve, P. R. W. J., Davey, C. M. Forsyth and B. M. Paterson. “The Synthesis of a Bis(thiosemicarbazone) Macrocyclic Ligand and the Mn(II), Co(II), Zn(II) and 68Ga(III) Complexes”, 2021 Molecules 26(12), 3646. https://doi.org/10.3390/molecules26123646
M. L. Grieve and B. M. Paterson “The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy”, 2022 Australian Journal of Chemistry, 75(2), 65-88. https://doi.org/10.1071/CH21184